Your browser doesn't support javascript.
loading
SEAKER cells coordinate cellular immunotherapy with localized chemotherapy.
Lane, Isabel C; Jan, Max.
Affiliation
  • Lane IC; Massachusetts General Hospital Center for Cancer Research, Boston, MA, USA; Massachusetts General Hospital Department of Pathology, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Jan M; Massachusetts General Hospital Center for Cancer Research, Boston, MA, USA; Massachusetts General Hospital Department of Pathology, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. Electronic address: mjan@mgh.harvard.edu.
Trends Pharmacol Sci ; 43(10): 804-805, 2022 10.
Article in En | MEDLINE | ID: mdl-35491262
Tumor antigen escape and T cell dysfunction limit the effectiveness of chimeric antigen receptor (CAR) T cell therapies. To overcome these challenges, Gardner et al. engineered synthetic enzyme-armed killer (SEAKER) cells to coexpress a CAR and a prodrug-activating enzyme to orchestrate a dual immunologic and pharmacologic attack at the tumor site.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy / Neoplasms Limits: Humans Language: En Journal: Trends Pharmacol Sci Year: 2022 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy / Neoplasms Limits: Humans Language: En Journal: Trends Pharmacol Sci Year: 2022 Type: Article Affiliation country: United States